NASDAQ:FHTX

Foghorn Therapeutics Stock Forecast, Price & News

$13.23

+0.16 (+1.22 %)

(As of 09/17/2021 12:00 AM ET)

Add

Compare

Today's Range

$12.88

▼

$14.09

50-Day Range

$8.33

▼

$13.92

52-Week Range

$8.01

▼

$28.26

Volume374,630 shs

Average Volume81,582 shs

Market Capitalization$488.72 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive FHTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Foghorn Therapeutics

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Up 6.7%
September 17, 2021 | americanbankingnews.com

Foghorn Therapeutics (NASDAQ:FHTX) Shares Up 6.8%
September 10, 2021 | americanbankingnews.com

Foghorn Therapeutics (NASDAQ:FHTX) Shares Gap Down to $13.68
September 7, 2021 | americanbankingnews.com

Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
September 1, 2021 | finance.yahoo.com

Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609
August 23, 2021 | finance.yahoo.com

Insiders who bought Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock in the last 12 months recover some losses, but still down US$35k
August 14, 2021 | nasdaq.com

Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update
August 10, 2021 | finance.yahoo.com

Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
August 3, 2021 | finance.yahoo.com

Could The Foghorn Therapeutics Inc. (NASDAQ:FHTX) Ownership Structure Tell Us Something Useful?
July 22, 2021 | finance.yahoo.com

Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021
July 9, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FHTX
Previous Symbol
CUSIPN/A
CIKN/A
Webfoghorntx.com
Phone617-586-3100
Employees95
Year FoundedN/A

Sales & Book Value

Annual Sales$430,000.00
Price / Sales1,136.55
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.08 per share
Price / Book3.24

Profitability

EPS (Most Recent Fiscal Year)($6.23)
Net Income$-68,800,000.00
Net Margins-8,565.02%
Return on Equity-140.74%
Return on Assets-40.76%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares36,940,000
Market Cap$488.72 million
Next Earnings Date12/3/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.23 out of 5 stars

Medical Sector

322nd out of 1,350 stocks

Pharmaceutical Preparations Industry

152nd out of 664 stocks

3.5 Analyst's Opinion

Consensus Rating
Foghorn Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.67, Foghorn Therapeutics has a forecasted upside of 86.4% from its current price of $13.23.
Amount of Analyst Coverage
Foghorn Therapeutics has received no research coverage in the past 90 days.

4.5 Community Rank

Outperform Votes
Foghorn Therapeutics has received 13 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Foghorn Therapeutics has received 6 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Foghorn Therapeutics has received 68.42% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Foghorn Therapeutics and other stocks. Vote “Outperform” if you believe FHTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FHTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Foghorn Therapeutics does not currently pay a dividend.
Dividend Growth
Foghorn Therapeutics does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
16.12% of the stock of Foghorn Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
63.38% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Foghorn Therapeutics are expected to grow in the coming year, from ($2.43) to ($2.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Foghorn Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Foghorn Therapeutics is -2.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Foghorn Therapeutics has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Foghorn Therapeutics (NASDAQ:FHTX) Frequently Asked Questions

Is Foghorn Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Foghorn Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Foghorn Therapeutics stock.
View analyst ratings for Foghorn Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Foghorn Therapeutics?

Wall Street analysts have given Foghorn Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Foghorn Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Foghorn Therapeutics' next earnings date?

Foghorn Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, December 3rd 2021.
View our earnings forecast for Foghorn Therapeutics.

What price target have analysts set for FHTX?

4 equities research analysts have issued 12-month price targets for Foghorn Therapeutics' shares. Their forecasts range from $23.00 to $27.00. On average, they expect Foghorn Therapeutics' stock price to reach $24.67 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price.
View analysts' price targets for Foghorn Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Foghorn Therapeutics' key executives?

Foghorn Therapeutics' management team includes the following people:

Dr. Douglas G. Cole M.D., Founder & Chairman (Age 61, Pay $16.03k)
Mr. Adrian H. B. Gottschalk, Pres, CEO & Director (Age 45, Pay $790.27k)
Dr. Cigall Kadoch Ph.D., Founder & Director (Age 35, Pay $226.81k)
Dr. Carl Peter Decicco Ph.D., Chief Scientific Officer (Age 61, Pay $676.24k)
Mr. Michael J. LaCascia, Chief Legal Officer (Age 56, Pay $119.42k)
Dr. Samuel Agresta M.D., M.P.H., Chief Medical Officer (Age 49, Pay $511.57k)
Dr. Gerald R. Crabtree, Founder & Member of Scientific Advisory Board
Dr. Allan Reine, Chief Financial Officer (Age 46)
Mr. Carlos Costa, Sr. VP, People & Organization
Dr. Steven F. Bellon Ph.D., Sr. VP of Drug Discovery (Age 56)

Who are some of Foghorn Therapeutics' key competitors?

Some companies that are related to Foghorn Therapeutics include Cassava Sciences (SAVA), Deciphera Pharmaceuticals (DCPH), NGM Biopharmaceuticals (NGM), Trillium Therapeutics (TRIL), Nuvalent (NUVL), Centessa Pharmaceuticals (CNTA), Dynavax Technologies (DVAX), IVERIC bio (ISEE), uniQure (QURE), Dicerna Pharmaceuticals (DRNA), Zymeworks (ZYME), Global Blood Therapeutics (GBT), MorphoSys (MOR), Prelude Therapeutics (PRLD) and Nurix Therapeutics (NRIX).
View all of FHTX's competitors.

When did Foghorn Therapeutics IPO?

(FHTX) raised $120 million in an initial public offering (IPO) on Friday, October 23rd 2020. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Foghorn Therapeutics' stock symbol?

Foghorn Therapeutics trades on the NASDAQ under the ticker symbol "FHTX."

Who are Foghorn Therapeutics' major shareholders?

Foghorn Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (6.89%), BlackRock Inc. (2.97%), Morgan Stanley (2.65%), Morgan Stanley (2.65%), Vanguard Group Inc. (1.86%) and Geode Capital Management LLC (0.65%). Company insiders that own Foghorn Therapeutics stock include Abu Dhabi Investment Authority and Carl Decicco.
View institutional ownership trends for Foghorn Therapeutics.

Which major investors are selling Foghorn Therapeutics stock?

FHTX stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, and FMR LLC.
View insider buying and selling activity for Foghorn Therapeutics or view top insider-selling stocks.

Which major investors are buying Foghorn Therapeutics stock?

FHTX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Morgan Stanley, Vanguard Group Inc., Geode Capital Management LLC, State Street Corp, Northern Trust Corp, and Nuveen Asset Management LLC. Company insiders that have bought Foghorn Therapeutics stock in the last two years include Abu Dhabi Investment Authority, and Carl Decicco.
View insider buying and selling activity for Foghorn Therapeutics or or view top insider-buying stocks.

How do I buy shares of Foghorn Therapeutics?

Shares of FHTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Foghorn Therapeutics' stock price today?

One share of FHTX stock can currently be purchased for approximately $13.23.

How much money does Foghorn Therapeutics make?

Foghorn Therapeutics has a market capitalization of $488.72 million and generates $430,000.00 in revenue each year. The company earns $-68,800,000.00 in net income (profit) each year or ($6.23) on an earnings per share basis.

How many employees does Foghorn Therapeutics have?

Foghorn Therapeutics employs 95 workers across the globe.

What is Foghorn Therapeutics' official website?

The official website for Foghorn Therapeutics is foghorntx.com.

How can I contact Foghorn Therapeutics?

The company can be reached via phone at 617-586-3100 or via email at [email protected].

This page was last updated on 9/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here